The role of 18F-FLT in cancer imaging: Does it really reflect proliferation?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 3, 2008, Pages 523-526

  Dimitrakopoulou Strauss, Antonia ^a   Strauss, Ludwig G ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CELL DNA; DRUG METABOLITE; FLUORO 3' DEOXY 3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GLUCOSE; HEXOKINASE; KI 67 ANTIGEN; THYMIDINE; THYMIDINE KINASE 1; TRACER; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

BONE MARROW; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DNA SYNTHESIS; DRUG HALF LIFE; DRUG TRANSPORT; DRUG UPTAKE; EXPERIMENTAL NEOPLASM; FIBROSARCOMA; GLUCOSE METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; LABELING INDEX; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; NONHODGKIN LYMPHOMA; NONHUMAN; NOTE; PANCREAS ADENOCARCINOMA; SENSITIVITY ANALYSIS; SOFT TISSUE SARCOMA; SPINAL CORD METASTASIS; ANIMAL; NEOPLASM; PATHOPHYSIOLOGY; SCINTISCANNING;

ANIMALS; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; HUMANS; NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 43349095522     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0679-8     Document Type: Note

References (20)

1. Been LB, Suurmeijer AJH, Cobben DCP, Jager PL, Hoekstra HJ, Elsinga PH. (18F)FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004;31:1659-72.
2. Christman D, Crawford EJ, Friedkin M, Wolf AP. Detection of DNA synthesis in intact organisms with positron-emitting (methyl-11C)thymidine. Proc Natl Acad Sci U S A 1972;69:988-92.
3. 18FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging 2004;31:169-78.
4. 8F-FDG and thymidine analogs: promise and pitfalls. J Nucl Med 2003;44:1432-4.
5. Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 2005;32:663-71.
6. Belt JA, Marina NM, Phelps DA, Crawford CR. Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul 1993;33:235-52.
7. Strauss LG, Klippel S, Pan L, Schönleben K, Haberkorn U, Dimitrakopoulou-Strauss A. Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection? Eur J Nucl Med Mol Imaging 2007;34:868-77.
8. Munch-Petersen B, Tyrsted G, Cloos L. Reversible ATP-dependent transition between two forms of human cytosolic thymidine kinase with different enzymatic properties. J Biol Chem 1993;268:15621-5.
9. Barthel H, Cleij MC, Collingridge DR, Hutchinson C, Osman S, He Q, et al. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8.
10. Lu L, Samuelsson L, Bergström M, Sato K, Fasth K-J, Langström B. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. J Nucl Med 2002;43:1688-98.
11. Quon A, Chang ST, Kamaya A, Dick DW, Loo BW Jr, Gambhir SS, et al. Pilot evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer. Eur J Nucl Med Mol Imaging 2007; in press.
12. Seitz U, Wagner M, Neumaier, et al. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[(18)F]fluoro-3′-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 2002;9:1174-81.
13. Choi SJ, Kim JS, Kim JH, Oh SJ, Lee JG, Kim CJ, et al. 18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005;32:653-9.
14. Cobben DCP, Elsinga PH, Suurmeijer AJH, Vaalburg W, Maas B, Jager PL, et al. Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′-deoxy-l-thymidine. Clin Cancer Res 2004;10:1685-90.
15. Buchmann I, Neumaier B, Schreckenberger M, Reske S. 18F]3′-deoxy- 3′-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations-a pilot study. Cancer Biother Radiopharm 2004;19:436-42.
16. Dittman H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, Horger M, et al. (18F)FLT PET for diagnosis and staging of thoracic tumors. Eur J Nucl Med Mol Imaging 2003;30:1407-12.
17. Buck AK, Hetzel M, Schirrmeister H, Halter G, Möller P, Kratochwill C, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 2005;32:525-33.
18. Been LB, Elsinga PH, deVries J, Cobben DCP, Jager PL, et al. Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy- 3′-fluoro-l-thymidine ((18)F-FLT)-a pilot study. Eur J Surg Oncol 2006;32:39-43.
19. Francis DL, Visvikis D, Costa DC, Arulampalam TH, Townsend C, Luthra SK, et al. Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003;30:988-94.
20. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65:4202-10.